



Scan the QR code to follow our WeChat Official Account



Scan the QR code to follow our Wechat Channels



Scan the QR code to follow our Weibo Official Account

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Add: Building A, Fosun Hi-Tech Park,
No.1289 Yishan Road Shanghai, P.R.China

Post Code: 200233
Tel: +86-21-33987000
Fax: +86-21-33987020
Our Official Website: www.fosunpharma.com

INNOVATION FOR GOOD HEALTH



CONTENTS

- About Fosun Pharma 03
- Innovative R&D 13
- Global business landscape 17
- Integrated development 21
- ESG & Sustainability 37

A global innovation-driven pharmaceutical and healthcare industry group

ABOUT FOSUN PHARMA

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma's innovative products mainly covered core therapeutic areas such as oncology (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease).

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of "Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote key business and rapidly enhance operational and asset efficiency, and is committed to becoming a first-class enterprise in the global major pharmaceutical and healthcare market.





Mission

Better Health for
Families Worldwide



Vision

We are committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets



Values

Care for life
Continuous Innovation
Pursuit of Excellence
Sustainable Partnership



OUR INNOVATION MILESTONES

Entered pharmaceutical manufacturing field



· Entered pharmaceutical distribution and retail business

01099.HK



2002
2004

2009

Innovation and R&D milestones



Accelerated internationalization

02196.HK
H-share listed on the Hong Kong Stock Exchange



INTUITIVE FOSUN
直观复星

Sisram Medical:
The first Israeli company listed on HKEx

2012
2017

2017

Held a stake in Gland Pharma

2019



02696.HK
· Henlius H-Share listed on Hong Kong Stock Exchange
· Han Li Kang (Rituximab injection), 1st biosimilar in China

2020

A number of innovative products have been approved for marketing

· Gland Pharma listed on the main board of BSE limited and the main board of National Stock Exchange of India (NSE: GLAND;BSE: GLAND)

· Collaborated with BioNTech entered into the mRNA-based vaccine field

2021



· Yi Kai Da (Axicabtagene Ciloleuceel Injection) the first CAR-T cell therapy approved by NMPA for launch

2022

Innovative Achievements Continuously Implemented Benefiting More Patients

· The first self-developed innovative monoclonal antibody, Han Si Zhuang (Serplulimab Injection) was approved by NMPA for launch



2023

- Argesun®
The Second-Generation Artesunate Injection has been launched
- The manufacture of Da Vinci surgical system was officially localized
- Bei Wen (keverprazan hydrochloride tablets)
- Pei Jin (telpegfilgrastim injection)
- Yi Xin Tan (sacubitril valsartan sodium tablets)



2024

- Ion robotic bronchoscopy was approved in China
- Collaborate with Shenzhen Municipal Guidance Fund to establish a 5 billion RMB biopharmaceutical industry fund



*As of December 31, 2023



BOARD OF DIRECTORS



Mr. Wu Yifang
Executive Director and Chairman



Mr. Wang Kexin
Executive Director, Co-Chairman



Mr. Chen Qiyu
Non-Executive Director



Mr. Yao Fang
Non-Executive Director



Mr. Xu Xiaoliang
Non-Executive Director



Mr. Pan Donghui
Non-Executive Director



Ms. Guan Xiaohui
Executive Director, Vice Chairman



Mr. Wen Deyong
Executive Director, Chief Executive Officer



Ms. Li Ling
Independent Non-Executive Director



Mr. Tang Guliang
Independent Non-Executive Director



Mr. Wang Quandi
Independent Non-Executive Director



Mr. Yu Tze Shan Hailson
Independent Non-Executive Director



BOARD OF SUPERVISORS



Ms. Ren Qian
Chief Supervisor



Mr. Guan Yimin
Supervisor



Mr. Chen Bing
Supervisor

*As of February 1, 2024



MANAGEMENT TEAM



Mr. Wen Deyong
Executive Director, Chief Executive Officer



Mr. Li Shengli
Executive President, Chief Growth Officer,
Co-Chairman of Shanghai Fosun Health and
Technology (Group) Co.,Ltd




Mr. Wang Xingli, MD, PhD
Executive President,
Co-CEO of Innovative Medicines Division,
CEO of Global R&D Center



Mr. Wenjie Zhang
Executive President,
Co-CEO of Innovative Medicines Division



Ms. Feng Rongli
Executive President,
CHO and General Manager of
Human Resources Department



Ms. Li Jing
Executive President,
CEO of Established Medicines Manufacturing and
Supply Division



Mr. Wang Donghua
Senior Vice President,
Chief Strategic Enabler (CSEO)



Mr. Li Dongjiu
Senior Vice President,
Director of Pharmaceutical Commerce
Admin Station Committee



Mr. Liu Yi
Senior Vice President,
Chairman and CEO of
Medical Devices Division



Mr. Hu Hang
Senior Vice President,
CEO of Shanghai Fosun Health and Technology(Group)Co.,Ltd. ,
Chairman and CEO of Shanghai Fosun Healthcare (Group) Co.,
Ltd. , Director of Foshan Fosun Chancheng Hospital



Mr. Bao Qingui
Senior Vice President,
Chairman of Medical Diagnosis Division



Mr. RONG YANG
Senior Vice President,
CEO of Fosun Pharma USA Inc.



Ms. Dong Xiaoxian
Vice President,
Secretary of the Board, Joint Secretary,
Director of the Board Secretary Office



Ms. Su Li
Vice President,
Executive President of Established Medicines
Manufacturing & Supply Division



Mr. Ji Hao
Vice President,
General Manager of
Anti-Corruption & Supervision Department



Ms. Zhu Yue
Vice President,
General Manager of the Legal Department



Mr. Xu Aihua
Vice President



Ms. Lv Lilang
Vice President,
Co-CEO of Medical Devices Division

*As of February 1, 2024



The annual R&D expenditure was

5,937 ^(RMB) million



Fosun Pharma has over **3,400** R&D personnels over **1,800** personnels with master's degrees or above representing approximately **8.65%** of the total employees



Over **70** major pipeline projects on innovative drugs and biosimilars (calculated by indication)




INNOVATIVE R&D



Fosun Pharma leverages open innovation models such as independent research and development, cooperative development, licensing, and deep incubation to connect with global scientific talent, leading technologies, and high-value products. Through integrated management of innovative R&D projects by its global research centers, Fosun Pharma enriches its pipeline of innovative products, enhances the research and clinical development capabilities of FIC and BIC new drugs, and accelerates the research, development, and practical implementation of innovative technologies and products.

Independent R&D, Cooperative Development, License-in, In-Depth Incubation



*As of December 31, 2023

Building an open and global innovative R&D system

Independent R&D



Cooperative Development



License-in&out

License-in

AMGEN 安进 Otezla (Apremilast Tablets)
Pang Bi Fu (Etelcalcetide Hydrochloride Injection)



Cooperation on various overseas innovative products such as Immunosuppressant Grafalon (Anti-human T-lymphocyte rabbit immunoglobulin injection), bifunctional HER2-sialase fusion protein



License-out



- Granted KG bio the exclusive development and commercialization rights for Serplulimab Injection (PD-1) in 10 countries in Southeast Asia. In August 2023, further expanded to include 12 countries in the Middle East and North Africa region.
- In October 2023, a commercialization licensing agreement was reached with Intas for the Serplulimab injection, covering Europe and India.



- Granted Intas Pharmaceuticals Ltd. exclusive commercialization rights in the U.S. and Canada
- Granted Accord exclusive commercialization rights in Europe, parts of countries in Middle East and North Africa and some CIS countries



- Cooperated with Getz Pharma the commercialization rights for Han Da Yuan (adalimumab injection), covering the 11 emerging market countries in Asia, Africa and Europe



- Granted Eurofarma, the leading pharmaceutical company in Brazil, the commercialization rights for Han Li Kang (rituximab injection), Han Qu You (trastuzumab injection), Han Bei Tai (bevacizumab injection) in 16 countries in Latin America, actively expanding the market in Latin America



- Granted Organon exclusive commercialization rights for pertuzumab biosimilar HLX11 and disuzumab biosimilar HLX14 worldwide except in China



- Granted Abbott semi-exclusive commercialization rights for Han Li Kang and Han Qu You in Brazil

Early-stage Investment & In-depth Incubation

Early-stage Investment

Participated in overseas healthcare professional funds for access to leading technologies globally with potential license-in and other collaboration opportunities.



Fosun Health Capital, the first VC fund established by Fosun Pharma, aiming to invest in innovative drug products and technologies with rapid growth potential at the initial and expansion phases. Fosun Health Capital was established in August 2020 with its first fund of RMB1.5 billion and was fully closed in February 2021.

Venture Team Mode

Collaborating with scientists or professors to convert intangible assets into equity and work with funds to incubate companies



License Mode

Introducing leading domestic or foreign products and forming platform companies in China within specific areas



JV Mode

Contributing capital jointly, or establishing joint ventures



In-depth Incubation





Europe

- Gland Pharma fully acquired Cenexi and entered into Europe-based CDMO at the end of April
- Granted the exclusive development and commercialization rights for Serplulimab Injection (PD-1) in agreed European Countries and India to Intas with upfront payments of €42 million in total

Africa

- Established 5 regional distribution hubs with about 800 people in the commercialization team
- Constructing the Côte d'Ivoire Industrial Park in order to achieve localizing products manufacturing and distributing in Africa

India

- Gland Pharma Dexrazoxane for Injection and Zoledronic acid for injection were approved in Chinese Mainland in February and December of 2023 respectively; filed several other products in Chinese Mainland
- Actively promote transformation of Gland Pharma's products into complex injectables

America

- Generic Drugs: collaborated with 5 major wholesalers and 16 GPOs
- Innovative Drugs:
 - Self-developed and manufactured trastuzumab biosimilar HERCESSI™ (HLX02, trade name: HANQUYOU in China and Zercepac® in Europe) has been approved for marketing by the FDA
 - Therapies with Serplulimab Injection (PD-1) are in global multi-center clinical trials; initiated head-to-head bridging study for ES-SCLC in the U.S
 - Establishing an innovative pharmaceutical team in the United States to cover medical affairs, market access, sales, etc., to support the U.S. commercialization of Serplulimab Injection (PD-1)

Aesthetic Medical Platform Sisram

- Strengthened global direct sales teams, improved market control and launched high-margin products drives gross margin (61.1% in 2023, 57.0% in 2022)
- 12 direct sales markets including US, UK, UAE, etc.; completed the acquisition of Chinese direct sales channel in June
- The proportion of direct sales revenue increased from 36% in 2016 to 66% in 2022 and further to 78% in 2023



ROOTED IN CHINA SERVING THE WORLD

● Localization of innovation

Accelerating the localization of innovation to benefit more Chinese patients

FOSUNKite —复星凯特生物—

- First CAR-T cell therapy approved in China, approved 2L r/r LBCL in June. Yi Kai Da (ejilunsai injection) is the first CAR-T cell therapy product approved in China. The new second-line indication was approved in June 2023 (treatment of adults patients with large B-cell lymphoma (r/r LBCL) refractory to first-line immunochemotherapy or relapsing within 12 months of first-line immunochemotherapy)
- Treated over 600 patients. Included in over 75 commercial insurances and 100 citizen insurances, over 160 treatment centers covering more than 25 provinces and cities
- Introduced Pay for Performance (PFP), exploring innovative payment models for high-value treatment in January 2024

INTUITIVE FOSUN 直观复星

- Speed up the domestic production of Da Vinci Surgical Robot
- The domestic medical device was approved by the NMPA in June 2023. The first domestic Da Vinci Xi System was launched in October 2023. In 2023, 55 units were installed in Chinese Mainland and Hong Kong China.
- The Ion Endoluminal System was approved by the NMPA in March 2024, assisting the early diagnosis of lung cancer

FOSUN INSIGHTEC 复星医视特

- Fosun Medtech collaborated with Insightec in December to establish a JV in China, dedicated to the commercialization, clinical application and R&D in the Chinese Mainland, Hong Kong and Macao, aiming to treat patients with Parkinson's diseases and essential tremor
- cutting-edge technology in non-invasive transcranial therapy, MRI-guided focused ultrasound brain therapy system (FUS)



- Accelerating localization production and transformation in China
- Actively respond to the policy of Hainan Free Trade Port, and build a Chinese operations center integrating sales, production and R&D
- Completing the import and introduction, domestic transformation and domestic upgrading of a number of respirators. Series of products provided solutions for mild to moderate respiratory failure

● Global Manufacturing System

Fosun Pharma is actively integrating manufacturing capacities to build a large-scale, cost-competitive manufacturing system and finally realize the overall planning of global capacity. As of the end of 2023, Fosun Pharma had 9 manufacturing lines that passed GMP inspection by FDA and EMA and other main stringent regulatory authorities.

- Multiple production lines for API and formulation of Yao Pharma, Wanbang and Guilin Pharma received GMP certifications from the U.S.FDA, Europe, etc
- Integrating manufacturing facilities to improve efficiency, accelerating the construction of Xuzhou Industrial Park Formulation Plant and of API facilities in Xuzhou Xingnuo, Hunan Dongting and Chongqing Changshou
- Commercialization capacity of Henlius is 48,000L; Xuhui plant has passed dual GMP certification in both China and Europe
- Fosun Adgenvax received Drug Manufacturing Licence and the Drug Operation Licence, supporting its subsequent commercialization of in-line vaccine products
- Constructing the Côte d'Ivoire Industrial Park in order to achieve localizing products manufacturing and distributing in Africa
- Gland Pharma received GMP certifications from the U.S., EU, Japan, Australia, etc.; Gland Pharma fully acquired Cenexi and entered into Europe-based CDMO



The revenue from pharmaceutical manufacturing segment was

30,222^(RMB) million

The R&D investment in pharmaceutical manufacturing segment was

5,172^(RMB) million

Accounting for

17.11%

of the revenue in the pharmaceutical manufacturing segment



PHARMACEUTICALS MANUFACTURING

● Three Major Segments with Specific Focuses

Innovative Medicines

Integrated management of the innovative drug R&D teams and innovative pipeline by the Global R&D Center
Focus on **small-molecule drug, antibody/ADC, cell therapy, RNA** and other technology platforms

Established Medicines Manufacturing & Supply

Focus on the R&D of differentiated and high-tech barrier products, and increase the proportion of **first/first, difficult complex preparations and improved new drugs**
Promote the integration of production lines and capacity, continue to reduce costs and increase efficiency

Vaccine

An independent R&D system has been established with two major technology platforms, **bacterial vaccines and viral vaccines**, as the core
Further expand vaccine pipeline through cooperative development and enhance vaccine industrialization capabilities

*As of December 31, 2023

Innovative Achievements Continuously Implemented Benefiting More Patients

In 2023, Fosun Pharma continued to promote innovation transformation, and revenue from key innovative products maintained rapid growth, including Han Si Zhuang (serplulimab injection), trastuzumab injection (trade name in Chinese mainland: Han Qu You), and Su Ke Xin (avatrombopag maleate tablets).



Han Si Zhuang (Serplulimab Injection)

The world's first PD-1 inhibitor approved for 1L ES-SCLC



Han Li Kang (Rituximab Injection)

The first China-developed biosimilar



Han Qu You (trastuzumab injection)

The first China-developed mAb biosimilar approved both in China and EU



YI KAI DA (Axicabtagene Ciloleuceel Injection)

First CAR-T cell therapy approved in China



Su Ke Xin (Avatrombopag Maleate Tablets)

Fosun Pharma's first innovative small molecule drug introduced



Akynzeo (netupitant and palonosetron hydrochloride capsules)

The world's first dual-channel fixed-dose combination oral compound preparation that simultaneously blocks both NK-1 receptors and 5-HT3 receptors



Pei Jin (Telpegfilgrastim Injection)

Long-lasting recombinant human granulocyte colony-stimulating factor product



Grafalon

Prevention of graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation



Bei Wen (Keverprazan Hydrochloride)

First domestic self-developed potassium-competitive acid blocker (P-CAB)



Yi Xin Tan (Sacubitril Valsartan Sodium Tablets)

The first-line drug for the treatment of heart failure and hypertension in an innovative crystalline form



Otezla (Apremilast Tablets)

First oral PDE4 inhibitor approved for the treatment of plaque psoriasis in China



Etelcalcetide Hydrochloride Injection

Next-generation calcimimetic

Antimalaria series of Artesunate injection



Malaria prevention

SPAQ-CO® Dispersible

More than 250 million children in Africa have benefited from "Seasonal Malaria Chemoprevention Program", effectively reducing the incidence of malaria in children under 5 years old in the high season.



Malaria Treatment

D-ARTEPP®

In 2019, it was pre-certified by the World Health Organization



Severe Malaria Treatment

Artesun® & Argesun® artesunate injection

The second generation of artesunate for injection (Argesun) obtained WHO PQ in June 2023, and was registered and approved in 21 countries. As of December 2023, the Group has supplied over 340 million doses of artesunate for injection across the world. Save more than 68 million patients with severe malaria

FOSUN MEDTECH
复星医疗器械

Treatment & Care by Side

Fosun MedTech has initially formed three major business divisions with medical aesthetics, respiratory care and professional medical care.



medical aesthetics



respiratory care



professional medical care



MEDICAL DEVICES

Medical Aesthetic Area

Building a Wellness Ecosystem

Sisram Medical (01696.HK), the core platform for medical aesthetics, continues to build a wellness ecosystem through innovative product portfolio, diversified market strategy and global strategic layout, based on four core businesses lines of energy-based devices, injectables, aesthetics and digital dentistry, and personal care.



FY2023 revenue of \$ **359.3** million, increase of **1.4%** YoY 

Four core businesses line



Energy-bases Devices **Alma**

The world's leading provider for energy-based medical aesthetic devices



Personal Care **LMNT.**

New launched personal care brand



Aesthetics and Digital Dentistry **Copulla**

A brand new dental platform





Injectables **REVANCE IBSA Raziel**

Layout injectables track

Respiratory Care

Layout of Respiratory Health Ecological Industry

Product line-China 



Professional Medical Devices & Consumables

Providing solutions from pre-hospital care to hospital specialty

In the field of professional medical devices, closely focusing on clinical needs, The Medical devices Segment provides comprehensive solutions from pre-hospital care to hospital surgery, covering first-aid units, medical equipment focusing on core tracks such as neurosurgery /orthopedics /oncology, high-end surgical robotic systems and medical consumables, comprehensive layout of China's medical technology and service market.

INTUITIVE FOSUN 直观复星

Dan Vinci Surgical System

- Launch of domestically-manufactured Da Vinci Surgical System. In 2023, 55 Systems were installed in Chinese Mainland and Hong Kong China
- By the end of 2023, over 360 Systems were installed, providing Da Vinci Surgical Systems and robotic-assisted surgery learning and training for over 3,000 healthcare professionals
- Since FDA approval in 2000, as of 2023, 8,606 systems were installed worldwide, and performed over 14.02 million surgeries



Ion Robotic Bronchoscopy

- The robotic-assisted bronchoscopy platform, Ion, was approved by FDA in 2019
- On March 21, 2024, The Ion was approved by the NMPA



FOSUN DIAGNOSTICS
复星诊断



Integrating Innovative Diagnostic Technology to Protect Global Health




MEDICAL DIAGNOSIS



4+2” Platform Construction



Construct a supporting product group of diagnostic instruments and reagents clusters covering key areas of six major product lines





Five R&D and Manufacturing Bases



Shanghai Base



Changsha Base



Taizhou Base




Hefei Base



Suzhou Abcarta


Adhering to independent innovation, actively layout large instruments and equipments

- In May 2023, Fosun Diagnostics newly launched the delicate, comprehensive, intelligent, flexible Laboratory Automation System F-A7000 series.
- Through the perfect collaboration of different testing equipment, the overall testing efficiency of the laboratory can be improved in terms of sample turnaround time, instrument operation efficiency, layout design, etc., effectively alleviating the shortage of laboratory personnel resources and equipment pressure, and helping Chinese medical institutions to achieve a comprehensive upgrade of operation management and clinical diagnosis and treatment performance.

 Clinical Chemistry

 Immunoassay

F-A7000series
Laboratory automation system



F-C2000
High-speed
biochemical analyzer



F-C800p
Automated integrated
biochemical analyzer



F-i6000
Ultra-high-speed
immunoassay analyzer



FCi6200
Ultra-high-speed biochemical and immunoassay analyzer




FCi3800
Automated integrated biochemical and immunoassay analyzer



F-i3000
Automated chemiluminescence
immunoassay analyzer



F-i1000
Automated chemiluminescence
immunoassay analyzer

 Microbiology



I-SPOT.TB[®] mycobacterium
tuberculosis specific cellular
immune reaction test reagents
Enzyme-linked immunospot
counter ES-15




NG-Test CARBA5[®]
carbapenemases test



Automated microbial
antimicrobial susceptibility
analyzer Droplet 48

 Molecule



F-AutoFlex96
nucleic acid extractor



SLAN-96S & SLAN-96P
automatic medical
PCR system



Hepatitis C virus nucleic
acid quantification and
genotyping test kit



Hepatitis B
virus nucleic acid test kit

 Pathology



PathAb
Pathological
Antibody



PathKit
Pathology
Test Kit



FAIP-48T
automated
immunohistochemical
stainer



FAIP-48TF
automated
immunohistochemical
stainer

 POCT



GULP-1



Relif



GU-2




MLA-1

FOSUN HEALTH
复星健康

**Medical group as The Core,
Smart Healthcare and Insurance as The Support**

To create leading medical services in Asia
to meet the diversified needs of users



**HEALTHCARE
SERVICES**





Members of Fosun Health Organization.

- ① Foshan Fosun Chancheng Hospital
- ② Guangzhou Fosun Chancheng Hospital
- ③ Shenzhen Hengsheng Hospital
- ④ Zhuhai Chancheng Hospital
- ⑤ Suqian Zhongwu Hospital
- ⑥ Yueyang Guangji Hospital
- ⑦ Wuhan Jihe Hospital
- ⑧ Chongqing Shinrong Plastic Surgery Hospital
- ⑨ Shanghai Starkids Children's Hospital
- ⑩ Xuzhou Star Hospital
- ⑪ Anhui Jimin Cancer Hospital
- ⑫ Wenzhou Geriatric Hospital
- ⑬ Suqian Rehabilitation Hospital
- ⑭ Suzhou Sungin Rehabilitation Hospital
- ⑮ Ningbo Sungin Garden Nursing Home
- ⑯ Jinan Xingqi Diagnostics
- ⑰ Shanghai BFC Medical Centre
- ⑱ Beijing Joyful Way Clinic



*审图号:GS(2019)1823号

A medical network with extensive coverage and leading expertise

The layout of the Greater Bay Area, Yangtze River Delta, and other regions. Total number of beds in holding hospitals: 6,548; Hold 8 Internet hospital licenses.

Fosun Health ranked among the Top three of "Top 100 Social Medical and Hospital Groups" for three consecutive years from 2021 to 2023; Foshan Fosun Chancheng Hospital has been ranked first GAHA's "Non-public Hospitals" competitiveness list for six consecutive years from 2018 to 2023.

In the first half of 2023, Foshan Fosun Chancheng Hospital became the first designated medical institution in Foshan for the "Hong Kong and Macao Medicine and Equipment Connect" policy; StarKids Children's Hospital Shanghai began operations, specializing in gynecology and obstetrics; Shinrong Plastic Surgery Hospital became the first non-public medical institution in the country to be registered for GCP-compliant drug and medical device clinical trials; Guangzhou Xinshi Hospital entered into a strategic cooperation with Guangdong Pharmaceutical University, renamed as "Guangdong Pharmaceutical University Guangzhou Fosun Chancheng Hospital".

Important equity participation/member institutions under management



Huaihai Hospital Management Group
(formerly Xuzhou Coal Mining Hospital Group)



Janjia Healthcare Investment&Management Co.,Ltd
(formerly Sinopharm Holding Medical Investment Management Co., Ltd.)



* Data as of the end of December 2023, Excluding Janjia Healthcare Investment&Management Co.,Ltd

Innovation is the most important responsibility of Fosun Pharma's sustainable development


A
MSCI ESG rating

A-
Hang Seng ESG rating

- Ranked among the top tier in the healthcare industry - pharmaceuticals and biotechnology sector
- Selected into the Hang Seng (China A) Corporate Sustainability Benchmark Index
- The Hang Seng (China A) Corporate Sustainability Index
- The Hang Seng (Mainland and HK) Corporate Sustainability Index.

 **ESG & Sustainability**

Fosun Pharma officially released its first ESG and Sustainable Development Report



Awards & Honors

China's Top 100 Pharmaceutical Industry in 2022
No.2
China's Ministry of Industry and Information Technology

All-Star list of the Most Admired Chinese Companies
FORTUNE

2023 China Best Managed Companies
DELOITTE